Nebius Group N.V. is expected to report $57.7M in Q1 revenue, up 52% sequentially from $37.9M in Q4 2024. Click here to find ...

Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business ...

Good afternoon, everyone and thank you for joining our conference call to discuss BioStem Technologies' first quarter 2025 financial results and corporate highlights. Leading the call today will be ...